Menu

BeyondSPX has rebranded as EveryTicker. We now operate at everyticker.com, reflecting our coverage across nearly all U.S. tickers. BeyondSPX has rebranded as EveryTicker.

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (3734)

Company Market Cap Price
LLY Eli Lilly and Company
Lilly is a large, diversified global pharmaceutical company with a core high-revenue portfolio.
$876.40B
$927.04
+2.55%
JNJ Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
$564.21B
$234.19
-0.15%
ABBV AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
$368.29B
$208.44
-0.26%
AZN AstraZeneca PLC
AZN is a large-cap pharmaceutical company with a diversified, global drug portfolio and a robust R&D pipeline.
$317.44B
$204.81
+2.16%
MRK Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
$295.53B
$119.10
+3.15%
UNH UnitedHealth Group Incorporated
UNH is primarily a health insurer and provides medical benefit plans through UnitedHealthcare.
$294.06B
$324.52
+2.57%
TMO Thermo Fisher Scientific Inc.
Thermo Fisher directly manufactures and sells diagnostic instruments and equipment used in clinical labs.
$197.85B
$526.48
+2.03%
AMGN Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
$191.32B
$355.23
+1.67%
NVO Novo Nordisk A/S
Novo Nordisk is a leading large-cap pharmaceutical company with blockbuster GLP-1 products Wegovy and Ozempic, a core driver of its revenue and growth.
$180.05B
$40.51
-1.04%
GILD Gilead Sciences, Inc.
Trodelvy is a TROP2-targeted antibody-drug conjugate (ADC), a core oncology modality.
$170.77B
$137.61
-0.68%
ABT Abbott Laboratories
Abbott's cardiology device portfolio includes leadless pacemakers (AVEIR), MitraClip/TMVR systems and other interventional devices, representing core revenue drivers in Cardiology Devices.
$168.34B
$96.86
+1.46%
← Previous
1 2 3 ... 38
Next →
Showing page 1 of 38 (3734 total stocks)

Loading company comparison...

Loading research report...

JNJ Johnson & Johnson

Judge Denies Bayer’s Bid to Block Johnson & Johnson’s Erleada Advertising Claims

Apr 18, 2026
LLY Eli Lilly and Company

Eli Lilly’s Foundayo Secures 1,390 U.S. Prescriptions in First Week After Launch

Apr 18, 2026
LLY Eli Lilly and Company

Eli Lilly Reports Cardiovascular Safety Success for Foundayo in Phase 3 ACHIEVE‑4 Trial

Apr 17, 2026
MRK Merck & Co., Inc.

Merck Secures European Commission Approval for ENFLONSIA, a Long‑Acting RSV Antibody

Apr 17, 2026
ABT Abbott Laboratories

Abbott Reports Q1 2026 Earnings: Revenue $11.16 B, EPS $1.15, Guidance Adjusted Downward

Apr 16, 2026
JNJ Johnson & Johnson

MeiraGTx Reacquires Gene‑Therapy Asset from Johnson & Johnson for $25 Million

Apr 16, 2026
LLY Eli Lilly and Company

FDA Requests Additional Safety Data on Eli Lilly’s Obesity Pill Foundayo

Apr 16, 2026
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Launches Applied Biosystems PowerFlex Thermal Cycler

Apr 16, 2026
ABBV AbbVie Inc.

AbbVie Secures Exclusive Global Pain‑Therapy License Deal with Haisco, Excluding China, Hong Kong, Macau

Apr 14, 2026
AMGN Amgen Inc.

Amgen Settles Denosumab Patent Litigation with Henlius and Organon

Apr 14, 2026
GILD Gilead Sciences, Inc.

PEPFAR and Global Fund Commit to Expand Gilead’s Lenacapavir Access to 3 Million People

Apr 14, 2026
JNJ Johnson & Johnson

Johnson & Johnson Beats Q1 2026 Earnings, Raises Full‑Year Guidance

Apr 14, 2026
LLY Eli Lilly and Company

Eli Lilly to Acquire Houston‑Based Biotech CrossBridge Bio for Up to $300 Million

Apr 14, 2026
NVO Novo Nordisk A/S

Novo Nordisk Partners with OpenAI to Accelerate Drug Development and Operational Efficiency

Apr 14, 2026
LLY Eli Lilly and Company

Eli Lilly Reports Positive Phase 3 Results for Jaypirca in Relapsed CLL/SLL

Apr 13, 2026
MRK Merck & Co., Inc.

Merck and Daiichi Sankyo Receive FDA Priority Review for Ifinatamab Deruxtecan in Extensive‑Stage Small Cell Lung Cancer

Apr 13, 2026
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Expands Clinical Research Capabilities Through Partnership with HealthVerity

Apr 13, 2026
ABBV AbbVie Inc.

AbbVie Presents Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine‑gynx at SGO 2026

Apr 12, 2026
JNJ Johnson & Johnson

Johnson & Johnson Unveils New Clinical Data for TECNIS PureSee IOL at ASCRS 2026

Apr 11, 2026
ABT Abbott Laboratories

Abbott Ordered to Pay $53 Million in Infant Formula Litigation; Verdict Delivered April 9, 2026

Apr 10, 2026
AMGN Amgen Inc.

Amgen Gains China Approval for Tarlatamab, Expanding Oncology Footprint

Apr 10, 2026
NVO Novo Nordisk A/S

EMA Approves Wegovy Injection for 48‑Hour Room‑Temperature Storage, Enhancing Distribution Flexibility

Apr 10, 2026
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power 100,000‑Participant Biobank Study

Apr 10, 2026
LLY Eli Lilly and Company

Eli Lilly Launches First U.S. Oral GLP‑1 Weight‑Loss Pill, Foundayo, on April 9

Apr 09, 2026
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Expands Global Reach with Distribution Deal for Saladax Biomedical’s Therapeutic Drug Monitoring Assays

Apr 08, 2026
ABBV AbbVie Inc.

Allergan Aesthetics Opens Third U.S. Training Center in Austin, Texas

Apr 07, 2026
GILD Gilead Sciences, Inc.

Gilead Acquires Tubulis for $5 B to Expand Antibody‑Drug Conjugate Platform

Apr 07, 2026
JNJ Johnson & Johnson

Johnson & Johnson Launches VARIPULSE Pro Pulled‑Field Ablation System in Europe

Apr 07, 2026
NVO Novo Nordisk A/S

Novo Nordisk Launches Higher‑Dose Wegovy HD Injection Nationwide

Apr 07, 2026
UNH UnitedHealth Group Incorporated

CMS Finalizes 2.48% Medicare Advantage Rate Increase, Boosting UnitedHealth Group’s Medicare Business

Apr 07, 2026
AMGN Amgen Inc.

Amgen Reports 77% Proptosis Response in Phase 3 Trial of Subcutaneous TEPEZZA

Apr 06, 2026
AZN AstraZeneca PLC

AstraZeneca’s EMERALD‑3 Trial Shows Significant Progression‑Free Survival Benefit for Unresectable Liver Cancer

Apr 03, 2026
MRK Merck & Co., Inc.

Merck Gains EU Approval for KEYTRUDA® Combination Therapy in Platinum‑Resistant Ovarian Cancer

Apr 03, 2026
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Launches Gibco CTS Compleo Fill and Finish System for Cell‑Therapy Manufacturing

Apr 03, 2026
AMGN Amgen Inc.

Amgen and Zai Lab Announce Global Phase 1b Study of DLL3‑Targeting ADC Combined with IMDELLTRA® in Extensive‑Stage Small Cell Lung Cancer

Apr 02, 2026
GILD Gilead Sciences, Inc.

Gilead Extends Arcellx Tender Offer Deadline to April 24, 2026

Apr 02, 2026
MRK Merck & Co., Inc.

Merck Commences Pivotal Trial of MK‑8748 (Tiespectus) for Neovascular Age‑Related Macular Degeneration

Apr 02, 2026
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Unveils New Cell Therapy and Biologics Platforms

Apr 02, 2026
LLY Eli Lilly and Company

Eli Lilly Secures FDA Approval for Oral GLP‑1 Weight‑Loss Pill Foundayo

Apr 01, 2026
NVO Novo Nordisk A/S

NICE Endorses Wegovy for Cardiovascular Risk Reduction, Expanding NHS Access to 1.2 Million Patients

Apr 01, 2026
AMGN Amgen Inc.

FDA Issues Liver Injury Warning for Amgen’s Tavneos, 76 Cases Reported

Mar 31, 2026
LLY Eli Lilly and Company

Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8 Billion Deal

Mar 31, 2026
MRK Merck & Co., Inc.

Merck & Co. Announces $838 Million Antibody Discovery Partnership with Infinimmune

Mar 31, 2026
NVO Novo Nordisk A/S

Novo Nordisk Launches Discounted Wegovy Subscription Program for Self‑Pay Patients

Mar 31, 2026
TMO Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Unveils Glacios 3 Cryo‑TEM, Enhancing Cryo‑EM Accessibility

Mar 31, 2026
ABT Abbott Laboratories

Abbott Expands Oncology Test Access via Flatiron EMR Integration

Mar 30, 2026
JNJ Johnson & Johnson

Johnson & Johnson and Royalty Pharma Announce $500 Million Co‑Funding Deal for Dual‑Target Autoimmune Antibody

Mar 30, 2026
LLY Eli Lilly and Company

Eli Lilly Secures $2.75 Billion AI‑Driven Drug Discovery Deal with Insilico Medicine

Mar 30, 2026
MRK Merck & Co., Inc.

Merck’s Enlicitide Achieves 64.6% LDL Reduction in Phase 3 Trial, First Oral PCSK9 Inhibitor

Mar 30, 2026
LLY Eli Lilly and Company

Eli Lilly’s Taltz and Zepbound Combination Shows Strong Efficacy in Psoriatic Arthritis Trial

Mar 29, 2026